ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 in specific populations of advance solid tumors with c-MET alterations as monotherapy.
10 Primary · 5 Secondary · Reporting Duration: Up to 12 months
Experimental Treatment
40 Total Participants · 1 Treatment Group
Primary Treatment: Cohort 1: ABN401 · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: